Propanc Biopharma Provides Shareholder Update
1. Propanc Biopharma successfully completed IPO and is listed on Nasdaq. 2. The company plans Phase 1B study for PRP in advanced cancer patients in 2026. 3. Propanc has raised $4 million from its recent share offering. 4. CEO emphasizes strategies to strengthen financial position and long-term growth. 5. PRP targets various cancers, presenting a potential market of $18.1 billion by 2029.